Oxaliplatin Clinical Trials

4 recruiting

Oxaliplatin Trials at a Glance

8 actively recruiting trials for oxaliplatin are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Beijing, Beijing, and Guangzhou. Lead sponsors running oxaliplatin studies include Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Australasian Gastro-Intestinal Trials Group, and AC Camargo Cancer Center.

Browse oxaliplatin trials by phase

Treatments under study

About Oxaliplatin Clinical Trials

Looking for clinical trials for Oxaliplatin? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Oxaliplatin trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Oxaliplatin clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 3

Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer

Gastric Cancer (GC)Adjuvant ChemotherapyOxaliplatin+2 more
Ruijin Hospital387 enrolled5 locationsNCT07366528
Recruiting
Phase 2

QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT

BevacizumabHepatecellular CarcinomaRALOX-HAIC(Hepatic Arterial Infusion Chemotherapy With Raltitrexed and Oxaliplatin+3 more
Nanfang Hospital, Southern Medical University38 enrolled1 locationNCT07327788
Recruiting
Not Applicable

Study to Evaluate the Use of Surgical Gloves for the Prevention of Oxaliplatin-Induced Peripheral Neuropathy

Colon CancerOxaliplatin-induced Peripheral Neuropathy
AC Camargo Cancer Center84 enrolled1 locationNCT07285356
Recruiting
Early Phase 1

Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy

Metastatic Colorectal Cancer (CRC)Oxaliplatin Induced Peripheral Neuropathy in Cancer PatientsPeripheral Neuropathy Due to Chemotherapy
Fox Chase Cancer Center30 enrolled1 locationNCT07167446
Recruiting
Phase 2

Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors

Hepatocellular CarcinomaTislelizumabOxaliplatin+3 more
Zhejiang Cancer Hospital35 enrolled1 locationNCT05920863
Recruiting
Phase 2

NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC

Advanced CancerPancreatic AdenocarcinomaCapecitabine+5 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences30 enrolled1 locationNCT06405490
Recruiting
Phase 2

XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC

CapecitabineTislelizumabBevacizumab+2 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences52 enrolled1 locationNCT05970302
Recruiting
Phase 2

OXTOX: Can Oxaliplatin neurotoxicity be reduced with ibudilast in people with metastatic colorectal cancer – a phase II randomised study

Neurotoxicity caused by oxaliplatin in patients with metastatic colorectal cancer
Australasian Gastro-Intestinal Trials Group100 enrolled10 locationsACTRN12619000566134